CORONA
CORONA REMEDIES LIMITED
Each stock's 10,000-path forecast, rendered as light.
CORONA REMEDIES LIMITED (CORONA) Stock Analysis & Case Study
Is CORONA a good buy? The data-driven verdict.
CORONA REMEDIES LIMITED (CORONA) trades at ₹1,847,on the numbers it worth a closer look, a Downstox Snapshot Score of 60/100.
On the numbers, CORONA REMEDIES LIMITED (CORONA) worth a closer look, a Downstox Snapshot Score of 60/100, weighing expensive at 56.7× earnings, ROE of 29.5%, a 91% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
CORONA fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is CORONA overvalued? CORONA P/E vs its sector
CORONA's P/E of 56.7× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.54% dividend yield is below the peer median of 1.65%.
CORONA share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 0.5y of CORONA history (52%/yr drift, 34%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| CORONA 2027 | ₹1,908 | ₹2,977 | ₹4,624 | +59% |
| CORONA 2028 | ₹2,539 | ₹4,728 | ₹8,838 | +153% |
| CORONA 2029 | ₹3,495 | ₹7,553 | ₹16,138 | +304% |
| CORONA 2030 | ₹4,934 | ₹11,943 | ₹29,119 | +539% |
| CORONA 2031 | ₹7,033 | ₹19,154 | ₹51,777 | +925% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability CORONA goes up, or doubles?
The bull case for CORONA
- High return on equity (29.5%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise.
- Strong ROCE (33.3%) shows the core business earns well above its cost of capital.
- A 10,000-path probability model puts a 91% chance the price is higher in a year, with a median target of ₹2,977 (+59%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹16,138.
The bear case & risks
- A rich 56.7× P/E leaves a thin margin of safety if growth slows.
- A steep 15.1× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹3,495.
CORONA volatility & expected range, how bumpy is the ride?
Over the last 0.5 years CORONA compounded at 52%/year with annualized volatility of 34%. That volatility implies a 1-year 80% range of ₹1,908–₹4,624, the honest backbone behind any single price target.
CORONA price forecast, the full 60-month probability fan
CORONA price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds CORONA hits common targets within the simulated horizon?
Full multi-horizon detail on the CORONA price target & forecast page.
CORONA Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. CORONA scores 4/9,mixed financial health.
CORONA MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy CORONA with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.0% | 2.9× |
| ZerodhaCHEAPEST | 26.9% | 3.7× |
| DhanCHEAPEST | 26.9% | 3.7× |
Compare every broker on the CORONA MTF page.
CORONA vs peers,sector comparison
About CORONA REMEDIES LIMITED: sector, index & market-cap context
CORONA REMEDIES LIMITED (CORONA) is a small-cap NSE-listed company, and a constituent of the Nifty 200 index group, with a market capitalisation of ₹11,325 Cr. See more Nifty 200 stocks.
How the CORONA Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of CORONA REMEDIES LIMITED's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
CORONA analysis, FAQs
Is CORONA REMEDIES LIMITED (CORONA) a good buy?
On the numbers, CORONA REMEDIES LIMITED (CORONA) worth a closer look, a Downstox Snapshot Score of 60/100, weighing expensive at 56.7× earnings, ROE of 29.5%, a 91% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is CORONA overvalued or undervalued?
CORONA trades at 56.7× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the CORONA share price target for 2031?
CORONA's probability-weighted 2031 median target is ₹19,154, with an 80% range of ₹7,033–₹51,777 (10,000-path Monte-Carlo).
What is the probability CORONA doubles in 5 years?
The modelled probability of CORONA reaching ₹3,737 (2×) within 5 years is 98%.
What is the bull case for CORONA?
High return on equity (29.5%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise. Strong ROCE (33.3%) shows the core business earns well above its cost of capital. A 10,000-path probability model puts a 91% chance the price is higher in a year, with a median target of ₹2,977 (+59%).
What are the risks in CORONA?
A rich 56.7× P/E leaves a thin margin of safety if growth slows. A steep 15.1× price-to-book means most of the value is intangible/expectations, not assets on the books.